In a post-Congress conversation, web editor Nicole Raleigh spoke with Dr Corina Dutcus, senior vice president and oncology global clinical development lead at Eisai, who discussed the data and the ...

Investing.com -- Eisai Co (OTC: ESAIY ). stock rose 0.4% on the day after initially trading in the red, as investors digested the company’s quarterly results that showed strong growth in sales of its ...

Praxis Precision Medicines’ oral vormatrigine stopped 100% of seizures in 22% of patients in a Phase II trial. The RADIANT ...

AMR demands sustained commitment beyond conventional market incentives. It requires founders with deep personal conviction ...

Japanese drugmaker Sumitomo Pharma Company and Tokyo-based Racthera announced that on August 5, they had submitted an ...

New findings presented at the 2025 Alzheimer’s Association International Conference (AAIC) in Toronto spotlighted the long-term potential of two FDA-approved Alzheimer’s treatments for people with ...

Sudden unexpected death in epilepsy (SUDEP) is the most significant complication of epilepsy, with an incidence of 1.2 per ...

Catalyst Pharmaceuticals CPRX is scheduled to report its second-quarter 2025 earnings results on Aug. 6, after market close.

Epilepsy is a serious and common neurological condition, characterised by recurring, unprovoked seizures, affecting ...